Answers are grounded in this paper and cite their sources.
Clinical investigation demonstrates refractory vascular rejection mediated by AT1-receptor antibodies in kidney transplant recipients, suggesting therapeutic potential for receptor blockade.
A non-HLA, AT1-receptor-mediated pathway may contribute to refractory vascular rejection, and affected patients might benefit from removal of AT1-receptor antibodies or from pharmacologic blockade of AT1 receptors.
No takes yet. Share an insight, caveat, or question.
Dragun et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: